- Home
- PAVM vs MTVA Comparison
PAVM vs MTVA Comparison
Compare PAVM & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- MTVA
- Stock Information
- Founded
- PAVM 2014
- MTVA 2014
- Country
- PAVM United States
- MTVA United States
- Employees
- PAVM N/A
- MTVA N/A
- Industry
- PAVM Medical/Dental Instruments
- MTVA
- Sector
- PAVM Health Care
- MTVA
- Exchange
- PAVM Nasdaq
- MTVA NYSE
- Market Cap
- PAVM 12.0M
- MTVA 14.3M
- IPO Year
- PAVM 2016
- MTVA N/A
- Fundamental
- Price
- PAVM $0.59
- MTVA $0.74
- Analyst Decision
- PAVM Strong Buy
- MTVA Strong Buy
- Analyst Count
- PAVM 1
- MTVA 2
- Target Price
- PAVM $19.00
- MTVA $7.50
- AVG Volume (30 Days)
- PAVM 115.2K
- MTVA 62.8K
- Earning Date
- PAVM 08-11-2025
- MTVA 08-13-2025
- Dividend Yield
- PAVM N/A
- MTVA N/A
- EPS Growth
- PAVM N/A
- MTVA N/A
- EPS
- PAVM 0.96
- MTVA N/A
- Revenue
- PAVM $1,993,000.00
- MTVA N/A
- Revenue This Year
- PAVM N/A
- MTVA N/A
- Revenue Next Year
- PAVM $455.63
- MTVA N/A
- P/E Ratio
- PAVM $0.62
- MTVA N/A
- Revenue Growth
- PAVM N/A
- MTVA N/A
- 52 Week Low
- PAVM $0.54
- MTVA $0.60
- 52 Week High
- PAVM $1.90
- MTVA $4.41
- Technical
- Relative Strength Index (RSI)
- PAVM 44.90
- MTVA N/A
- Support Level
- PAVM $0.58
- MTVA N/A
- Resistance Level
- PAVM $0.62
- MTVA N/A
- Average True Range (ATR)
- PAVM 0.03
- MTVA 0.00
- MACD
- PAVM 0.00
- MTVA 0.00
- Stochastic Oscillator
- PAVM 55.90
- MTVA 0.00
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.